SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)

Also known as: ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca AZD1222

Active ingredient description

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Covid-19 vaccines
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX03

Medicines

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is the active ingredient of these drugs:

Drug
Countries

Austria France Ireland Lithuania Netherlands

Unique ingredient identifier (UNII)

B5S3K2V0G8 - AZD-1222